Drug intelligence / Profile preview

UMC119-10

Development stage: Preclinical
Lead developer: Meridigen Biotech
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

UMC119-10 is an allogeneic cell therapy candidate developed by Meridigen Biotech Corp., consisting of mesenchymal stem cells derived from the human umbilical cord (UC-MSCs). It is currently in preclinical development for the treatment of cerebral palsy (CP). The therapeutic rationale for UMC119-10 involves the ability of UC-MSCs to home to damaged neural tissues and release a cocktail of paracrine factors, including neurotrophic factors and anti-inflammatory cytokines. These factors are intended to mitigate neuroinflammation, provide neuroprotection to surviving neurons, and stimulate endogenous neural repair and plasticity, thereby potentially improving motor function and quality of life in patients with CP.

Other names: umbilical cord-derived mesenchymal stem cellsUC-MSC

Beyond the preview

Go deeper on UMC119-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UMC119-10.

Explore the full profile